

[] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *					2. Issuer Name and Ticker or Trading Symbol								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
PETERS WILLIAM J					Amphastar Pharmaceuticals, Inc. [AMPH]								Director		10%	Owner .		
(Last) (First) (Middle)				3. Date of Earliest Transaction (MM/DD/YYYY)							Y)	Officer (give title below) Other (specify below) CFO, EVP & Treasurer						
C/O AMPHA PHARMAC	EUTICA	LS, INC	., 1157	70				3/1	/202	23								
6TH STREE	(Stre	et)			4. I	fAn	nendme	nt, Date O	rigin	al Fil	ed (MM/I	DD/YYY	Y)	6. Individual o	r Joint/Gi	roup Filing ((Check Appl	icable Line)
RANCHO C	UCAMO			730										_X _ Form filed by Form filed by	One Repor	ting Person		
			Table I	- Non-	Der	ivati	ive Sec	urities Ac	quire	ed, Di	sposed	of, or E	ene	eficially Owner	d			
1. Title of Security (Instr. 3) 2. Trans.				2. Trans. I	E		Deemed ution , if any	3. Trans. Code (Instr. 8)		4. Sec or Dis (Instr.		Fo	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)			6. Ownership Form: Direct (D)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								Code	V	Amou	(A) o	Price	:				or Indirect (I) (Instr. 4)	(IIISU. 4)
Common Stock 3/1/2023					3		M		10974	I A	\$11.33	3	111588 (1)		D			
Common Stock 3/1/2023				3			S ⁽²⁾		10974	D	\$36.33	3	100614			D		
	Tab	le II - Deri	ivative	Securit	ies I	Bene			e.g.,	puts,	calls, w	arrant	s, oj	ptions, conver				
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deer Executio Date, if a		le		5. Numb Derivativ Acquired Disposed (Instr. 3,	ve Securities I (A) or I of (D)	e Securities (A) or of (D)		te Exercisable Expiration Date		es U ive S			9. Number of derivative Securities Beneficially Owned Following	Ownership Form of	Beneficial
	Security			Code		V	(A)	(D)	Date Exerc	eisable	Expiration Date	Title		Amount or Number of Shares		Reported Transaction(s) (Instr. 4)	or Indirect	
Employee Stock Option (right to buy)	\$11.33	3/1/2023		I	М			10974		<u>3)</u>	3/17/2026	Comr		10974	\$0	8826	D	

Explanation of Responses:

- (1) Includes 134 shares acquired under the Issuer's 2014 Employee Stock Purchase Plan on November 30, 2022.
- (2) The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2022.
- (3) Shares subject to the option are fully vested and immediately exercisable.

Reporting Owners

Reporting Owner Name / Address	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
PETERS WILLIAM J							
C/O AMPHASTAR PHARMACEUTICALS, INC.			CFO, EVP & Treasurer				
11570 6TH STREET			Cro, Evr & Treasurer				
RANCHO CUCAMONGA, CA 91730							

Signatures

/s/ William J. Peters 3/3/2023

**Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.